A Phase 4 interventional study of Rebif® and Rebif® in Multiple Sclerosis, Relapsing-Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-09-20.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 8th largest by enrollment, is the only one that started in 2014, is one of 13 in phase 4, and was the 17th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 80 across the 21 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 8 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2014, is one of 7 in phase 4, and was the 32nd registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 40 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS) as compared to the evening administration, in subjects with relapsing multiple sclerosis (RMS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rebif®
Drug: Rebif®
Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12
The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 12 is presented in statistical analysis section.
Time frame: Week 12
Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4 and 8
The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 4 and 8 is presented in statistical analysis section.
Time frame: Week 4 and 8
Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Subscale Scores Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 4, 8 and 12
MSTCQ was used as a tool to measure treatment satisfaction, focusing on attributes specific to MS medications. Following sub-scales were assessed: Injection site reactions (ISRs), Global side-effects, Benefits, Pain, Visual Analog Scale (VAS), and Rating of Pain. ISR subscale was defined as sum of scores for questions 17 to 20, with a minimum possible total score of 4 and a maximum possible total score of 20. Global side-effects subscale was defined as sum of scores for questions 21 to 23 with minimum possible total score of 3 and a maximum possible total score of 15. Benefits (question 35); description of pain (question 36); VAS (question 37); rating of pain (question 38) subscales ranged from minimum possible score of 1 and a maximum possible total score of 5. For each of the subscales, lower scores indicated better satisfaction. Difference between both the groups at Week 4, 8 and 12 for individual sub-scales is presented in statistical analysis section.
Time frame: Week 4, 8 and 12
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score at Week 4, 8 and 12
HADS was used to measure depression and anxiety in subjects. The scale was limited to 14 questions. Seven of the items related to anxiety and 7 related to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.
Time frame: Baseline, Week 4, 8 and 12
Change From Baseline in Fatigue Severity Scale (FSS) Score at Week 4, 8 and 12
FSS is a method designed to assess disabling fatigue in all the individuals. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each item assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.
Time frame: Baseline, Week 4, 8 and 12
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at Week 4, 8 and 12
PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. PSQI is a summary of 7 components. Each component is scored from 0 to 3, therefore PSQI has a range of 0 (better) to 21 (worse). Interpretation of the PSQI is that a score less than 5 is associated with good sleep quality and a score of 5 or greater is associated with poor sleep quality.
Time frame: Baseline, Week 4, 8 and 12
Change From Baseline in Multiple Sclerosis International Quality of Life (MusiQOL) Score at Week 4, 8 and 12
The MusiQoL is a validated 31-item questionnaire describing 9 dimensions: activities of daily living (8 items); psychological well-being (4 items); symptoms (3 items); relationships with friends (4 items); relationships with family (3 items); relationship with healthcare system (3 items); sentimental and sexual life (2 items); coping (2 items); and rejection (2 items). Each of the questions was answered using a 6-point Likert scale ranging from 1 (never/not at all) to 6 (always/very much). The scores of each dimension were obtained by computing mean of the item scores of dimension with negatively worded item scores reversed so that higher scores indicated higher health-related quality of life (QoL). All 9 dimension scores were linearly transformed to a 0 to 100 scale and the average of the 9 dimensions was used to give a Global Score ranging from 0 to 100, where higher scores indicated higher health-related quality of life (QoL).
Time frame: Baseline, Week 4, 8 and 12
Percentage of Subjects With Treatment Adherence at Week 4, 8 and 12
Adherence to treatment was calculated as 100 x the number of completed injections the subject administered divided by the expected number of injections. Treatment adherence was divided in two categories: percentage of subjects with less than (\<) 80 percent adherence and percentage of subjects with more than or equal to (\>=) 80 percent adherence.
Time frame: Week 4, 8 and 12
Change From Baseline in Circulating Levels of Cytokines at Week 12
Results are presented for three cytokines: leptin, resistin and adiponectin.
Time frame: Baseline and Week 12
Correlation Between Change From Baseline in Circulating Levels of Cytokines (Leptin, Resistin and Adiponectin) and in Flu Like Symptom (FLS) Score at Week 12
Correlation was assessed by using Pearson correlation coefficient. The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to MS medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction.
Time frame: Baseline and Week 12
Correlation Between Change From Baseline in Circulating Levels of Cytokines and in Other MSTCQ Items, HADS, FSS, PSQI and MusiQOL Scores at Week 12
Correlation was assessed by using Pearson correlation coefficient. MSTCQ, HADS, FSS, PSQI and MusiQOL are described in the above endpoints. Following abbreviations used in the categories: Global side-effects (GLOBSE); description of pain (PAINDESCR).
Time frame: Baseline and Week 12
Change From Baseline in Cytokines (Leptin and Resistin) Levels at Week 12
Results are presented for cytokines: leptin and resistin.
Time frame: Baseline and Week 12
Change From Baseline in Cytokine (Adiponectin) Level at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Hormone-Like Cytokine (Interleukin-6, 10 and 12) Levels at Week 12
Time frame: Baseline and Week 12
Change From Baseline in Total Sleep Time (TST) and Rapid Eye Movement (REM) Sleep Time at Week 12
Polysomnography (PSG) was performed for subjects who participated in the sub study. PSG is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.
Time frame: Baseline and Week 12
Correlation Between Change From Baseline in Cytokines (Leptin, Resistin and Adiponectin) and Hormone-like Cytokine Levels (Interleukin-6, 10 and 12), and TST and REM Sleep Time at Week 12
Correlations between change from baseline at Week 12 in TST or REM sleep and the area under the curve (AUC) calculated using the trapezoidal method for cytokine levels (i.e., leptin, resistin, adiponectin, Interleukin (IL)-12, IL 10, and IL 6) were analyzed using Pearson's correlation coefficient. Polysomnography (PSG) was performed for subjects who participated in the sub study.
Time frame: Baseline and Week 12
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug.
Time frame: Baseline up to Week 12
The study was conducted at 29 clinical trial sites in Italy.
| Milestone | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Started | 104 | 96 |
| Completed | 96 | 88 |
| Not completed | 8 | 8 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Therapeutic failure | 0 | 1 |
| Withdrew: Other | 1 | 3 |
The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 12 is presented in statistical analysis section.
| units on scale | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Difference in Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ) Flu Like Symptom (FLS) Score Between Rebif Morning Administration and Rebif Evening Administration Groups at Week 12 | 12.3 ± 3.87 | 11.8 ± 3.02 |
The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to multiple sclerosis (MS) medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction. Difference between Rebif Morning Administration and Rebif Evening Administration groups at Week 4 and 8 is presented in statistical analysis section.
| units on scale | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Week 4 | 12.4368 (11.7402 to 13.1333) | 11.0876 (10.3705 to 11.8046) |
| Week 8 | 13.0039 (12.3244 to 13.6834) | 11.6672 (10.9565 to 12.3779) |
MSTCQ was used as a tool to measure treatment satisfaction, focusing on attributes specific to MS medications. Following sub-scales were assessed: Injection site reactions (ISRs), Global side-effects, Benefits, Pain, Visual Analog Scale (VAS), and Rating of Pain. ISR subscale was defined as sum of scores for questions 17 to 20, with a minimum possible total score of 4 and a maximum possible total score of 20. Global side-effects subscale was defined as sum of scores for questions 21 to 23 with minimum possible total score of 3 and a maximum possible total score of 15. Benefits (question 35); description of pain (question 36); VAS (question 37); rating of pain (question 38) subscales ranged from minimum possible score of 1 and a maximum possible total score of 5. For each of the subscales, lower scores indicated better satisfaction. Difference between both the groups at Week 4, 8 and 12 for individual sub-scales is presented in statistical analysis section.
| units on scale | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| ISRs subscale Week 4 | 10.8459 (10.1609 to 11.5309) | 10.4456 (9.7177 to 11.1735) |
| ISRs subscale Week 8 | 11.5363 (10.8625 to 12.2101) | 11.4515 (10.7540 to 12.1490) |
| ISRs subscale Week 12 | 11.6380 (10.9720 to 12.3041) | 11.9625 (11.2598 to 12.6652) |
| Global side-effect subscale: Week 4 | 10.2144 (9.6771 to 10.7518) | 10.2852 (9.7276 to 10.8429) |
| Global side-effect subscale: Week 8 | 10.4111 (9.8698 to 10.9525) | 10.2214 (9.6567 to 10.7862) |
| Global side-effect subscale: Week 12 | 10.5879 (10.0456 to 11.1302) | 10.1782 (9.6132 to 10.7432) |
| Benefits: Week 4 | 3.1325 (2.7856 to 3.4794) | 3.5408 (3.1912 to 3.8905) |
| Benefits: Week 8 | 3.5779 (3.2207 to 3.9351) | 3.7137 (3.3622 to 4.0652) |
| Benefits: Week 12 | 3.6059 (3.2467 to 3.9652) | 3.6640 (3.3062 to 4.0218) |
| Description of pain: Week 4 | 4.3755 (3.2024 to 5.5485) | 3.7846 (2.5846 to 4.9847) |
| Description of pain: Week 8 | 5.3132 (4.1262 to 6.5003) | 6.0821 (4.8767 to 7.2875) |
| Description of pain: Week 12 | 5.7853 (4.6089 to 6.9617) | 5.6431 (4.4239 to 6.8624) |
| VAS: Week 4 | 11.8837 (7.6691 to 16.0983) | 11.2293 (6.8280 to 15.6305) |
| VAS: Week 8 | 17.2316 (12.9597 to 21.5035) | 19.4610 (15.0359 to 23.8860) |
| VAS: Week 12 | 16.1757 (11.9054 to 20.4460) | 21.5953 (17.1359 to 26.0547) |
| Rating of pain: Week 4 | 1.3073 (1.1008 to 1.5138) | 1.3004 (1.0846 to 1.5162) |
| Rating of pain: Week 8 | 1.5653 (1.3553 to 1.7753) | 1.6522 (1.4356 to 1.8688) |
| Rating of pain: Week 12 | 1.4994 (1.2895 to 1.7094) | 1.7218 (1.5029 to 1.9407) |
HADS was used to measure depression and anxiety in subjects. The scale was limited to 14 questions. Seven of the items related to anxiety and 7 related to depression. Each item on the questionnaire was scored from 0-3 giving a total score between 0 and 21 for either anxiety or depression where higher score indicates more anxiety/depression.
| units on scale | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Anxiety score: Change at Week 4 | -0.6625 (-1.1976 to -0.1273) | -0.4604 (-1.0106 to 0.08968) |
| Anxiety score: Change at Week 8 | -0.7222 (-1.2688 to -0.1755) | -0.3763 (-0.9308 to 0.1782) |
| Anxiety score: Change at Week 12 | -0.6435 (-1.1879 to -0.09918) | 0.05023 (-0.5081 to 0.6085) |
| Depression score: Change at Week 4 | -0.1539 (-0.8083 to 0.5005) | 0.2211 (-0.4617 to 0.9038) |
| Depression score: Change at Week 8 | -0.2397 (-0.9062 to 0.4267) | 0.1999 (-0.4835 to 0.8833) |
| Depression score: Change at Week 12 | 0.1906 (-0.4778 to 0.8590) | 0.1162 (-0.5741 to 0.8066) |
FSS is a method designed to assess disabling fatigue in all the individuals. The Fatigue Severity Scale is a 9-item questionnaire developed to assess the level of fatigue due to neurological disease, were each item assessed on a 1-7 scale (1= no fatigue and 7= severe fatigue). The total score was calculated as the average of individual 9-items and ranged from 1 to 7 with a higher value indicating greater impairment due to fatigue.
| units on scale | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Change at Week 4 | 0.2089 (-0.05810 to 0.4759) | 0.06901 (-0.2010 to 0.3391) |
| Change at Week 8 | 0.2062 (-0.06211 to 0.4746) | 0.1366 (-0.1354 to 0.4085) |
| Change at Week 12 | 0.1464 (-0.1253 to 0.4182) | 0.1942 (-0.08036 to 0.4688) |
PSQI is a self-rated questionnaire which assess sleep quality and disturbances over a 1-month interval using seven clinically derived components of sleep difficulties: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction. PSQI is a summary of 7 components. Each component is scored from 0 to 3, therefore PSQI has a range of 0 (better) to 21 (worse). Interpretation of the PSQI is that a score less than 5 is associated with good sleep quality and a score of 5 or greater is associated with poor sleep quality.
| units on scale | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Change at Week 4 | -0.08889 (-0.7690 to 0.5912) | 0.5747 (-0.1653 to 1.3147) |
| Change at Week 8 | -0.4513 (-1.1161 to 0.2136) | 0.7092 (-0.01588 to 1.4343) |
| Change at Week 12 | 0.07841 (-0.6265 to 0.7833) | 0.4293 (-0.3270 to 1.1855) |
The MusiQoL is a validated 31-item questionnaire describing 9 dimensions: activities of daily living (8 items); psychological well-being (4 items); symptoms (3 items); relationships with friends (4 items); relationships with family (3 items); relationship with healthcare system (3 items); sentimental and sexual life (2 items); coping (2 items); and rejection (2 items). Each of the questions was answered using a 6-point Likert scale ranging from 1 (never/not at all) to 6 (always/very much). The scores of each dimension were obtained by computing mean of the item scores of dimension with negatively worded item scores reversed so that higher scores indicated higher health-related quality of life (QoL). All 9 dimension scores were linearly transformed to a 0 to 100 scale and the average of the 9 dimensions was used to give a Global Score ranging from 0 to 100, where higher scores indicated higher health-related quality of life (QoL).
| units on scale | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Global Score: Change at Week 4 | 1.6283 (-0.3761 to 3.6326) | 0.1174 (-1.9196 to 2.1544) |
| Global Score: Change at Week 8 | 1.1439 (-0.8780 to 3.1658) | -2.2945 (-4.3568 to -0.2321) |
| Global Score: Change at Week 12 | 0.9670 (-1.0753 to 3.0094) | -1.3948 (-3.4796 to 0.6900) |
Adherence to treatment was calculated as 100 x the number of completed injections the subject administered divided by the expected number of injections. Treatment adherence was divided in two categories: percentage of subjects with less than (\<) 80 percent adherence and percentage of subjects with more than or equal to (\>=) 80 percent adherence.
| Percentage of subjects | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| < 80 percent adherence at Week 4 | 3.3 | 5.9 |
| >= 80 percent adherence at Week 4 | 96.7 | 94.1 |
| < 80 percent adherence at Week 8 | 2.9 | 1.5 |
| >= 80 percent adherence at Week 8 | 97.1 | 98.5 |
| < 80 percent adherence at Week 12 | 4.8 | 6.3 |
| >= 80 percent adherence at Week 12 | 95.2 | 93.7 |
Results are presented for three cytokines: leptin, resistin and adiponectin.
| microgram per liter (mcg/L) | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Leptin: Change at Week 12 | -2.6 ± 3.42 | -2.6 ± 3.90 |
| Resistin: Change at Week 12 | -3.1 ± 3.31 | -3.0 ± 3.77 |
| Adiponectin: Change at Week 12 | 2.8 ± 6.38 | 2.8 ± 5.51 |
Correlation was assessed by using Pearson correlation coefficient. The MSTCQ was used as a tool to measure treatment satisfaction, focusing on the attributes specific to MS medications. The FLS subscale of MSTCQ was defined as the sum of the scores for questions 13 to 16 with a minimum possible total FLS score = 1 and a maximum possible total FLS score = 20. Lower score indicates lower flu like symptoms and better satisfaction.
| Correlation coefficient | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Leptin and FLS: Change at Week 12 | 0.08822 | 0.03944 |
| Resistin and FLS: Change at Week 12 | -0.20200 | -0.01069 |
| Adiponectin and FLS: Change at Week 12 | 0.04616 | -0.13571 |
Correlation was assessed by using Pearson correlation coefficient. MSTCQ, HADS, FSS, PSQI and MusiQOL are described in the above endpoints. Following abbreviations used in the categories: Global side-effects (GLOBSE); description of pain (PAINDESCR).
| Correlation Coefficient | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Leptin and MSTCQ-ISR: Week 12 | 0.00595 | -0.10214 |
| Resistin and MSTCQ-ISR: Week 12 | -0.22380 | 0.04855 |
| Adiponectin and MSTCQ-ISR: Week 12 | -0.13365 | -0.14865 |
| Leptin and MSTCQ-GLOBSE: Week 12 | 0.03121 | 0.21425 |
| Resistin and MSTCQ-GLOBSE: Week 12 | 0.20285 | -0.12730 |
| Adiponectin and MSTCQ-GLOBSE: Week 12 | 0.00169 | -0.06398 |
| Leptin and MSTCQ-benefits: Week 12 | 0.13023 | -0.10915 |
| Resistin and MSTCQ-benefits: Week 12 | -0.13544 | -0.15636 |
| Adiponectin and MSTCQ-benefits: Week 12 | 0.10726 | 0.04081 |
| Leptin and MSTCQ-PAINDESCR: Week 12 | 0.09118 | 0.01165 |
| Resistin and MSTCQ-PAINDESCR: Week 12 | -0.13918 | 0.04150 |
| Adiponectin and MSTCQ-PAINDESCR: Week12 | 0.07093 | 0.01535 |
| Leptin and MSTCQ-VAS: Week 12 | 0.34840 | -0.01433 |
| Resistin and MSTCQ-VAS: Week 12 | -0.15231 | 0.16220 |
| Adiponectin and MSTCQ-VAS: Week 12 | -0.07840 | 0.02109 |
| Leptin and MSTCQ-pain rating: Week 12 | 0.16675 | -0.14381 |
| Resistin and MSTCQ-pain rating: Week 12 | -0.23531 | 0.12355 |
| Adiponectin and MSTCQ-pain rating: Week12 | -0.08060 | -0.08718 |
| Leptin and HADS-anxiety: Week 12 | 0.00754 | -0.06360 |
| Resistin and HADS-anxiety: Week 12 | 0.02447 | 0.07986 |
| Adiponectin and HADS-anxiety: Week 12 | 0.06295 | 0.08818 |
| Leptin and HADS-depression: Week 12 | 0.05226 | -0.14953 |
| Resistin and HADS-depression: Week 12 | 0.01970 | -0.04154 |
| Adiponectin and HADS-depression: Week 12 | 0.03228 | 0.19209 |
| Leptin and FSS: Week 12 | 0.04256 | 0.14284 |
| Resistin and FSS: Week 12 | -0.23755 | -0.10961 |
| Adiponectin and FSS: Week 12 | -0.00326 | 0.03090 |
| Leptin and PSQI: Week 12 | 0.00873 | 0.00099 |
| Resistin and PSQI: Week 12 | -0.03765 | 0.12085 |
| Adiponectin and PSQI: Week 12 | 0.25795 | 0.24406 |
| Leptin and MusiQoL- Global: Week 12 | -0.25650 | 0.17917 |
| Resistin and MusiQoL-Global: Week 12 | 0.12190 | 0.21936 |
| Adiponectin and MusiQoL-Global: Week 12 | 0.07152 | -0.05924 |
Results are presented for cytokines: leptin and resistin.
| Nanogram/milliliter (ng/mL) | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Leptin: Change at Week 12 | -2.7826 (-6.1880 to 0.6227) | -0.7936 (-4.4371 to 2.8499) |
| Resistin: Change at Week 12 | -3.6628 (-5.3424 to -1.9831) | -5.8360 (-7.6339 to -4.0381) |
| microgram per milliliter (mcg/mL) | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Change From Baseline in Cytokine (Adiponectin) Level at Week 12 | 2.7093 (-1.0663 to 6.4848) | 4.3574 (0.3174 to 8.3975) |
| Pico gram/milliliter (pg/mL) | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Interleukin-6: Change at Week 12 | -0.5173 (-1.7940 to 0.7593) | -0.6970 (-2.0624 to 0.6683) |
| Interleukin-10: Change at Week 12 | -0.05819 (-0.5453 to 0.4290) | -0.6660 (-1.2999 to -0.03210) |
| Interleukin-12: Change at Week 12 | -0.3490 (-0.9115 to 0.2135) | -0.4384 (-0.9973 to 0.1204) |
Polysomnography (PSG) was performed for subjects who participated in the sub study. PSG is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine. Total sleep time is the total of all REM and non-REM sleep in a sleep episode.
| minutes | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Total Sleep Time: Change at Week 12 | 10.0 (-73.0 to 117.0) | 33.0 (-227.0 to 165.0) |
| REM sleep: Change at Week 12 | -3.0 (-207.0 to 9.0) | 6.0 (-67.0 to 288.0) |
Correlations between change from baseline at Week 12 in TST or REM sleep and the area under the curve (AUC) calculated using the trapezoidal method for cytokine levels (i.e., leptin, resistin, adiponectin, Interleukin (IL)-12, IL 10, and IL 6) were analyzed using Pearson's correlation coefficient. Polysomnography (PSG) was performed for subjects who participated in the sub study.
| Correlation Coefficient | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| AUC Leptin and TST: Week 12 | 0.10816 | 0.46984 |
| AUC Resistin and TST: Week 12 | -0.56278 | -0.05056 |
| AUC Adiponectin and TST: Week 12 | 0.17402 | 0.58181 |
| AUC IL-12 and TST: Week 12 | -0.44328 | 0.24717 |
| AUC IL-10 and TST: Week 12 | 1.00000 | NA |
| AUC IL-6 and TST: Week 12 | 0.18626 | -0.51662 |
| AUC Leptin and REM: Week 12 | 0.99732 | 0.63155 |
| AUC Resistin and REM: Week 12 | 0.22684 | -0.38234 |
| AUC Adiponectin and REM: Week 12 | 0.98335 | -0.05732 |
| AUC IL-12 and REM: Week 12 | 1.00000 | -0.76606 |
| AUC IL-10 and REM: Week 12 | -1.00000 | NA |
| AUC IL-6 and REM: Week 12 | 0.06269 | -0.34860 |
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug.
| Subjects | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| TEAEs | 82 | 77 |
| Serious TEAEs | 1 | 2 |
| TEAEs Leading to Death | 0 | 0 |
| TEAE leading to Discontinuation | 6 | 3 |
Collected over Baseline up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rebif Morning Administration | — | 1/104 (1%) | 77/104 (74%) |
| Rebif Evening Administration | — | 2/96 (2.1%) | 70/96 (72.9%) |
| Event | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 0/104 | 1/96 |
| Deep Vein ThrombosisVascular disorders | 0/104 | 1/96 |
| Influenza Like IllnessGeneral disorders | 1/104 | 0/96 |
| Event | Rebif Morning Administration | Rebif Evening Administration |
|---|---|---|
| Influenza Like IllnessGeneral disorders | 52/104 | 42/96 |
| HeadacheNervous system disorders | 23/104 | 16/96 |
| PyrexiaGeneral disorders | 15/104 | 11/96 |
| Injection Site ErythemaGeneral disorders | 14/104 | 8/96 |
| NauseaGastrointestinal disorders | 10/104 | 2/96 |
| MyalgiaMusculoskeletal and connective tissue disorders | 10/104 | 6/96 |
| InsomniaPsychiatric disorders | 2/104 | 9/96 |
| FatigueGeneral disorders | 9/104 | 2/96 |
| Alanine Aminotransferase IncreasedInvestigations | 4/104 | 7/96 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/104 | 7/96 |
The Intention to Treat Analysis Set (ITT) included all subjects enrolled into the study and assigned to the RebiSmart device.
| Age, Customized(subjects) | Rebif Morning Administration | Rebif Evening Administration | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| >=18 years to 64 years | 104 | 96 | 200 |
| >64 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Rebif Morning Administration | Rebif Evening Administration | Total |
|---|---|---|---|
| Female | 76 | 62 | 138 |
| Male | 28 | 34 | 62 |
Ran from May 2014 to primary completion in Apr 2016, 22 months.
Results were first posted in Sep 2018, 2 years 4 months after primary completion.
Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Multiple Sclerosis, Relapsing-Remitting →
Merck KGaA, Darmstadt, Germany →